News brief­ing: Ab­b­Vie and Roche's Ven­clex­ta scores an­oth­er FDA OK; Im­muno­Gen nabs Chi­na deal with $40M cash

Ab­b­Vie and Roche’s Ven­clex­ta has got­ten a new FDA thumbs up.

The pair an­nounced Mon­day that reg­u­la­tors have ap­proved the drug in com­bi­na­tion with azac­i­ti­dine or low-dose cy­tara­bine for new­ly-di­ag­nosed acute myeloid leukemia in adults who are 75 or old­er or those who can’t un­der­go in­ten­sive chemother­a­py. This fol­lows the drug’s ac­cel­er­at­ed ap­proval in 2018 and pos­i­tive da­ta from two Phase III con­fir­ma­to­ry tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER